Tesamorelin vs CJC-1295+Ipamorelin Blend
Both catalog entries target the growth-hormone axis, but through different receptor-engagement strategies. Tesamorelin is an FDA-approved GHRH analogue that acts solely through the GHRH receptor. The CJC-1295+Ipamorelin Blend combines a GHRH analogue with a ghrelin-receptor secretagogue for dual-axis GH stimulation. This page summarises the published research distinctions.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Pharmacological strategy | Single molecule: GHRH receptor agonist (trans-3-hexenoic acid modified GRF 1-44 analogue) | Two-compound blend: CJC-1295 No DAC (GHRH receptor) + Ipamorelin (ghrelin receptor GHS-R1a) |
| Receptor targets | GHRH receptor only | GHRH receptor (CJC-1295) + ghrelin receptor (Ipamorelin) |
| Development stage | FDA approved for HIV-associated lipodystrophy (visceral adipose reduction) | Neither component is FDA approved; both are research-stage compounds |
| GH-release mechanism | Amplified GH pulse amplitude via GHRH-receptor engagement on anterior pituitary somatotrophs | Dual-axis: pulse-amplitude amplification (CJC-1295) + pulsatile-release trigger (Ipamorelin) |
| Total vial mass | 10 mg | 10 mg |
| Common research routes | Subcutaneous injection | Subcutaneous injection |
| Ronin catalog format | Single-compound lyophilised vial | Lyophilised blend vial |
How they differ in mechanism
Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone with a trans-3-hexenoic acid modification at the N-terminus. The compound acts through the GHRH receptor on anterior pituitary somatotrophs to stimulate endogenous GH secretion. It has FDA approval for reducing visceral adipose tissue in HIV-associated lipodystrophy, with published clinical-trial data from the Falutz et al. Phase 3 program and subsequent safety extensions.
The CJC-1295+Ipamorelin Blend combines CJC-1295 No DAC (a modified GRF 1-29 GHRH analogue) with Ipamorelin (a selective ghrelin-receptor secretagogue). CJC-1295 engages the same GHRH-receptor axis as tesamorelin but with a different molecular structure. Ipamorelin adds ghrelin-receptor-mediated pulsatile GH release without significant ACTH, cortisol, or prolactin effects.
The key distinction is single-axis versus dual-axis GH modulation. Tesamorelin acts through the GHRH receptor alone with clinical-trial maturity. The blend adds ghrelin-receptor engagement for dual-axis coverage but lacks clinical-trial data for the combination. Tesamorelin also has a longer peptide chain (44 amino acids versus 29 for CJC-1295 No DAC) and a different pharmacokinetic profile.
How research has examined each
The tesamorelin literature is clinically mature, spanning the Falutz et al. Phase 3 trials (2007-2010), visceral-adiposity and metabolic-marker studies (Stanley et al., 2011, 2012), hepatic-enzyme improvements (Fourman et al., 2020), hepatic-transcriptomic characterisation (Stanley et al., 2021), neurocognitive-impairment investigation (Ellis et al., 2025), and integrase-inhibitor-era safety data (Russo et al., 2024).
The CJC-1295 literature covers GHRH-receptor pharmacology and GH-axis activation. The Ipamorelin literature covers ghrelin-receptor selectivity and gastrointestinal-motility studies. No published study examines the specific two-compound blend at the 1:1 mass ratio.
Tesamorelin has the most extensive clinical dataset of any GHRH analogue, with FDA-approved labelling. The blend is a sourcing-convenience format for dual-axis research without clinical-trial support for the combination.
Stacking considerations in research contexts
Tesamorelin and the CJC-1295+Ipamorelin Blend share overlapping GHRH-receptor pharmacology (tesamorelin and CJC-1295 both target the GHRH receptor). Co-administration would redundantly stimulate the same receptor axis while adding ghrelin-receptor stimulus from the Ipamorelin component. No published protocol describes this combination.
Sourcing both at Ronin
The Tesamorelin vial page provides 10 mg as a single compound. The CJC-1295+Ipamorelin Blend page provides 10 mg total of the two-compound blend. Both ship as lyophilised peptide in glass vials with certificate-of-analysis documentation. Both are research-grade reagents.
Frequently asked research questions
Do tesamorelin and CJC-1295 target the same receptor?
Yes. Both are GHRH analogues that engage the GHRH receptor on anterior pituitary somatotrophs. They differ in molecular structure and pharmacokinetic profile.
What does the blend add?
The blend adds Ipamorelin, which engages the ghrelin receptor for pulsatile GH release. This provides dual-axis GH stimulation versus the single-axis GHRH approach of tesamorelin alone.
Is tesamorelin FDA-approved?
Yes. Tesamorelin is FDA-approved for HIV-associated lipodystrophy. The Ronin vial is sold strictly as a research-grade reagent.
Has the CJC-1295+Ipamorelin combination been clinically tested?
No published clinical trial examines the specific combination. Both components have independent research literatures.
Are either approved for general weight management?
Neither is approved for general weight management. Tesamorelin is approved only for HIV lipodystrophy. Both Ronin vials are research-grade reagents.
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. [PMID 9849822]
- Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006. [PMID 16352683]
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007. [PMID 18057338]
- Falutz J et al. Tesamorelin pooled Phase 3 analysis. Journal of Clinical Endocrinology and Metabolism, 2010. [PMID 20554713]
- Stanley TL et al. Visceral fat reduction with tesamorelin improves metabolic profile. Clinical Infectious Diseases, 2012. [PMID 22495074]
- Ellis RJ et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV. Journal of Infectious Diseases, 2025. [PMID 39813152]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.